Back to top
more

Syros Pharmaceuticals (SYRS)

(Real Time Quote from BATS)

$5.00 USD

5.00
21,512

-0.10 (-1.96%)

Updated Apr 26, 2024 02:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Brokerage Reports

Research for SYRS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Syros Pharmaceuticals, Inc. [SYRS]

Reports for Purchase

Showing records 1 - 20 ( 220 total )

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

12/06/2023

Daily Note

Pages: 4

SELECT-AML-1 Triplet Combination Update Is Supportive of Phase 3 Start

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

11/15/2023

Company Report

Pages: 6

Optimistic Ahead of SELECT-AML-1 Update in December ’23

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

08/09/2023

Company Report

Pages: 6

SELECT-AML-1 Data in 4Q23, With SELECTMDS- 1 Pivotal CR Data in 3Q24; Reit Buy and $15 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

05/11/2023

Company Report

Pages: 6

Tamibarotene Continues to Improve its Position in AML and MDS; Reit. Buy and $15 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

03/03/2023

Company Report

Pages: 6

SELECT-AML-1 Data in 4Q23, Remains The Key Inflection Point; Reit Buy and $15 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

12/12/2022

Daily Note

Pages: 4

Positive SELECT-AML-1 During ASH’ 22 Bodes Well for Future Development

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 5.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

11/15/2022

Company Report

Pages: 6

Optimistic On SELECT-AML-1’s Data During ASH ’22; Reit. Buy and Raising Our PT to $20

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

07/12/2022

Company Report

Pages: 6

Merger with TYME Technologies + PIPE, Recharges Syros’ Pipeline; Reit Buy and Lowering our PT to $6

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

06/09/2022

Daily Note

Pages: 3

Healthcare Coverage Update - Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

05/17/2022

Company Report

Pages: 6

1Q2022 Update - Three Important Derisking Catalysts Expected in 2H2022

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 12.50

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

05/17/2022

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

05/17/2022

Company Report

Pages: 6

Data Rich 2H22 Should Counterbalance Pipeline De- Prioritizations; Reit Buy and Lower PT to $10 From $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

03/17/2022

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

03/16/2022

Company Report

Pages: 6

Catalysts Speak to Long-Term Growth Potential for Tamibarotene and Beyond

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

03/16/2022

Company Report

Pages: 5

4Q21 Updates - Key Readouts and Study Initiations in 2022, Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 5.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

03/16/2022

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

01/11/2022

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

01/10/2022

Company Report

Pages: 6

Key Clinical Catalysts Expected in 2022 Across Entire Pipeline

Provider: Roth Capital Partners, Inc.

Analyst: JALLAH Z

Price: 12.50

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

11/08/2021

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Syros Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

11/08/2021

Company Report

Pages: 6

SY-5609 Continues to Garner Investor Interest, While Pipeline Remains on Track; Reit Buy and $15 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 12.50

Research Provided by a Third Party